HER-2 oncogene encodes a transmembrane growth factor receptor that is overexpressed in 25 ± 30% of patients with primary breast and ovarian cancer. A murine monoclonal antibody, 4D5, to the extracellular domain of HER-2 receptor elicits cytostatic growth inhibition of tumor cells overexpressing HER-2 protein, but clinical use of this antibody is limited by genesis of human anti-mouse antibodies. To avoid this problem, a recombinant humanized 4D5 monoclonal antibody (rhuMAb HER-2) was developed and tested using a human tumor xenograft model. Human breast and ovarian cancer cells which overexpress HER-2 were inhibited in vivo by the rhuMAb HER-2 antibody. Tumor growth relative to control was reduced at all doses of antibody tested, and the magnitude of growth inhibition was directly related to dose of rhuMAb HER-2. Tumor growth resumed on termination of antibody therapy, indicating a cytostatic eect. To elicit a cytotoxic response, human breast tumor xenografts were treated with a combination of antibody and antitumor drugs, cisplatin or doxorubicin. The combination of antibody with either cisplatin or doxorubicin resulted in signi®-cantly greater growth inhibition, with the cisplatin combination demonstrating a greater response. In addition, therapy with cisplatin and antireceptor antibody elicited complete tumor remissions after 2 ± 3 cycles of therapy. The schedule of administration of antireceptor antibody and cisplatin was critical for occurrence of antibody-induced potentiation in cisplatin cytotoxicity. Enhanced killing of tumor cells was found only if antibody and drug were given in close temporal proximity. Since interference with DNA repair pathways may contribute to this receptor-enhanced chemosensitivity, repair of cisplatin-damaged reporter DNA (pCMVb) was determined in human breast cells. As in studies of antibody-enhanced cisplatin cytotoxicity in vivo, treatment with rhuMAb HER-2 blocked the repair of cisplatin-damaged DNA only if the antibody was administered in close temporal proximity to transfection of the drug-exposed reporter DNA. An alternative measure of DNA repair, unscheduled DNA synthesis, was also assessed. Treatment with either cisplatin or doxorubicin led to an increase in unscheduled DNA synthesis that was reduced by combined therapy with antireceptor antibody speci®c to HER-2-overexpressing breast cancer cells. Using a direct measure of DNA repair, therapy of HER-2-overexpressing cells with rhuMAb HER-2 also blocked the removal of cisplatininduced DNA adducts. Expression of p21/WAF1, an important mediator of DNA repair, was disrupted in breast cancer cells with HER-2 overexpression, but not in control cells, after treatment with HER-2 antibody, thus suggesting cross-communication between the HER-2 signaling and DNA repair pathways. These data demonstrate an in vivo antiproliferative eect of rhuMAb HER-2 on tumors that overexpress HER-2 receptor andIntroduction Breast cancer is a leading cause of cancer-related death in women, with ultimate treatment failure often related to resistance to conventional drug therapy (Harris et al., 1992) . Screening studies of human breast cancer tissue for genetic alterations revealed ampli®cation and/or overexpression of HER-2 (c-erbB-2/neu) proto-oncogene in 25 ± 30% of these cancers (Slamon et al., 1987 (Slamon et al., , 1989a Harris et al., 1992) . This molecular alteration correlates with a poor prognosis in that patients whose tumors contain the alteration have a shorter disease-free survival as well as a shorter overall survival (Slamon et al., 1987 (Slamon et al., , 1989a Lemoine et al., 1990; Press et al., 1993; Seshadri et al., 1993) . Moreover, results of recent clinical trials suggest that improvement in the outcome of patients with HER-2-overexpressing breast cancer may require treatment with signi®cantly higher doses of combination chemotherapy including anthracyclines and alkylating agents (Muss et al., 1994) .
The HER-2 proto-oncogene encodes a 185 000 kd transmembrane receptor tyrosine kinase with homology to epidermal growth factor receptor (Coussens et al., 1985; Semba et al., 1985) . This receptor has oncogenic potential which may be mediated through multiple genetic mechanisms including point mutations in the transmembrane domain (Bargmann et al., 1986) , truncation of the extracellular domain or overexpression of the non-mutated proto-oncogene (DiFiore et al., 1987; Hudziak et al., 1987; Yarden and Ullrich, 1988; Aaronson, 1991) . To date, no similar point mutations or truncations have been found in the HER-2 gene product in human cancers (Slamon et al., 1987; 1989a,b; Aaronson, 1991; Lofts and Gullick, 1992) . Rather, the alteration occurring in human malignant cells is overexpression of a normal gene product which is almost always but not uniformly due to gene ampli®cation (Slamon et al., 1989a,b; Lemoine et al., 1990; Pauletti et al., 1996) . In addition, overexpression of structurally-unaltered HER-2 gene leads to neoplastic transformation of both NIH3T3 cells (DiFiore et al., 1987; Hudziak et al., 1987) and immortalized, but non-transformed, human breast cells (Pierce et al., 1991) , indicating that this alteration may play a pathogenic role in promoting tumorigenicity of nonmalignant cells. Collectively, such data indicate that ampli®cation and/or overexpression of the HER-2 gene in human breast cells has a signi®cant eect on their biologic behavior and support the concept that this alteration plays a pathogenic role in increasing growth and tumorigenicity of human breast cancer cells.
Monoclonal antibodies against the extracellular domain of HER-2 membrane receptor can suppress tumorigenesis by HER-2-transformed NIH3T3 or NR6 cells (Drebin et al., 1988; Chazin et al., 1992) and speci®cally inhibit the growth of human breast carcinoma cells overexpressing the HER-2 gene product (Hudziak et al., 1989) . One murine monoclonal antibody, 4D5, has proven particularly eective in inhibiting growth of human tumor cells with HER-2 overexpression (Hudziak et al., 1989; Fendly et al., 1990) . However, available data indicate that eects of 4D5 antibody are cytostatic, not cytocidal. A second diculty with the antibody is that it is a mouse product and as such can elicit a human anti-mouse antibody response in patients receiving it. To circumvent this problem, a humanized version of 4D5 was developed . This engineered antibody contains only the antigen binding loops from murine antibody 4D5 and includes human variable region framework residues plus human IgG1 constant domains . Prior pharmacokinetic studies using murine monoclonal antibody 4D5 and rhuMAb HER-2 DeSantes et al., 1992) have been presented. These data show that in vivo serum clearance and permanence times are similar for humanized and native murine monoclonal antibodies. The ecacy of recombinant humanized monoclonal antibody to HER-2 receptor (rhuMAb HER-2) in vitro on human breast cells with overexpression of HER-2 receptor has also been demonstrated , but the eect of this preparation in vivo in preclinical animal studies remains to be established.
Independent studies show that ligands or antibodies to growth factor receptors can potentiate the cytotoxicity of chemotherapeutic drugs (Aboud-Pirak et al., 1988; Jensen and Linn, 1988; Christen et al., 1991; Hancock et al., 1991; Shepard et al., 1991; Pietras et al., 1994; Arteaga et al., 1994; Dixit et al., 1997; Mendelsohn and Fan, 1997) . Monoclonal antibodies to EGF receptor elicited an additive antitumor eect when given in combination with the anthracycline drug, doxorubicin (Aboud-Pirak et al., 1989) . A poorly understood but probable synergistic eect between monoclonal antibodies to EGF receptor and the chemotherapy drug, cisplatin, has also been reported (Aboud-Pirak et al., 1988) . The combined treatment resulted in a dramatic reduction in the number and size of epidermoid cancers grown as xenografts in athymic mice. Antibodies to HER-2 receptor have likewise been found to promote cell killing by cisplatin in tumors with overexpression of the HER-2 membrane receptor (Hancock et al., 1991; Shepard et al., 1991; Pietras et al., 1994) , and this eect has been shown to be a true synergistic interaction in both breast and ovarian cancer cells (Pietras et al., 1994) . Similarly, binding of certain growth factors to their cognate receptors has been reported to modulate cellular sensitivity to drugs. Incubation of human tumor cells with EGF has been found to increase sensitivity of these cells to the cytotoxic eects of cisplatin (Christen et al., 1991) . A biologic basis for these growth factor receptor-dependent changes in cellular sensitivity to DNA-interacting agents may be related to DNA repair mechanisms. Treatment of human neuroblastoma cells with NGF slows the removal of DNA adducts caused by the DNA-damaging drug, benzo(a)pyrene (Jensen and Linn, 1988) . Signal generated by activation of EGF receptor may also alter the rate of DNA repair in aected cells (Christen et al., 1991) . Work from our laboratory shows that anti-HER-2 receptor antibody-induced blockade of cisplatin-DNA adduct repair in cells with HER-2 overexpression leads to a two log increase in cytotoxicity of the drug (Pietras et al., 1994) . The speci®c molecular pathway for suppression of DNA repair triggered by ligand (or antireceptor antibody) interactions remains unde®ned. Cell responses to DNA damage are regulated, in part, by growth factor signaling pathways (Canman et al., 1995; Yen et al., 1997) . Recent reports show p53-independent activation of p21/WAF1 by mitogen-activated protein kinase (MAP kinase) signaling, and withdrawal of growth factors in vitro has been associated with down-regulation of p21/WAF1 expression and with enhanced cell killing in response to DNA damage (Canman et al., 1995; Liu et al., 1996) . Since maintenance of the integrity of DNA by repair is essential to cell survival, blockade of DNA repair triggered by peptide ligand or antireceptor antibody interactions could have application in cancer therapy.
The objectives of this study are to further evaluate the possibility of therapeutically exploiting these types of interactions to treat human cancer cells which overexpress the HER-2 receptor. The data presented demonstrate an in vivo cytostatic eect of rhuMAb-HER-2 in both breast and ovarian cancer cells with HER-2 overexpression. On the basis of independent work showing synergistic interaction between 4D5 antireceptor antibody and the DNA-damaging drug, cisplatin, resulting in enhanced cytotoxicity in tumors, the therapeutic advantage of rhuMAb HER-2 given in combination with cisplatin was tested with human breast tumor xenografts in athymic mice. In addition, comparison of rhuMAbHER-2 interaction with the DNA-intercalating drug, doxorubicin, was conducted. These studies reveal that the humanized antireceptor antibody enhances breast cancer cell killing in combination with some chemotherapeutic agents, with optimal antitumor eects occurring in combination with cisplatin. The HER-2 receptor-enhanced sensitivity to cisplatin occurred only if the two agents were administered in close temporal proximity, suggesting a critical biologic timeframe for promoting this phenomenon. These results provide a tentative schedule for testing and exploiting this novel therapeutic strategy in the clinic.
Results
Eect of recombinant humanized monoclonal antibody to HER-2 (rhuMAb HER-2) on growth of human breast and ovarian cells in athymic mice
Introduction of full-length human HER-2 cDNA into human breast cancer cells, MCF-7, results in 2 ± 5 copies of the gene per cell as compared to 5 ± 8 copies of the gene in SKBR3 cells, a non-engineered, naturally-ampli®ed cell line from patient material which expresses levels of the gene at the upper limit of that seen in human malignancies in nature . A similar level of ampli®cation is observed after transfection of CAOV3 cells with HER-2 retroviral vector. Levels of HER-2 overexpression as assessed by Western blot analyses demonstrate expression levels at or slightly below those seen in the naturally HER-2-ampli®ed, overexpressing SKBR3 cells. Such overexpression of the gene in murine cells has profound biologic eects, including signi®cant increments in DNA synthesis, cell growth, cloning eciency in soft agar, and in tumor formation in nude mice as reported previously (Chazin et al., 1992; Pietras et al., 1994 Pietras et al., , 1995 . Although MCF-7 parent and MCF-7 control cells form tumors in nude mice with estrogen treatment as reported before (Soule and McGrath, 1980) , overexpression of the HER-2 gene in human breast cancer cells (MCF-7/HER-2) leads to formation of tumors in nude mice at 10-times the size of those formed by MCF-7 parent or MCF-7 /CON cells after 28 days (P50.001; see Figure 1 ).
To determine if the rhuMAb HER-2 monoclonal antibody which is directed against the extracellular domain of the human gene had any eect on human cancer cells overexpressing the HER-2 gene, studies were performed using this antibody to treat nude mice implanted with the engineered human breast and ovarian cancer cells. Overexpressing MCF-7 human breast or overexpressing CaOV3 human ovarian cancer cells were injected subcutaneously at a dose of 3.5 ± 5.0610 7 cells/animal in the mid-back region of 3-month-old female Swiss nude mice which had been primed for 7 days with estradiol-17b. Following injection of cells, a period of 7 days elapsed to allow formation of tumor nodules. Animals were then randomized into six uniform groups based on animal weight and tumor volume at the start of the experiment. Monoclonal antibody and control solution were administered by intraperitoneal injection. RhuMAb HER-2 was tested at total doses of 3, 10, 30 and 100 mg/kg and compared to the known in vivo inhibitory eects of the murine 4D5 antibody. Control injections included huIgG1, total dose 100 mg/kg, and murine MAb 4D5, total dose 25 mg/kg. As indicated in Materials and methods, our choices for dose and schedule of therapy were based on results of prior pharmacokinetic studies using murine monoclonal antibody 4D5 and rhuMAb HER-2 DeSantes et al., 1992) . Test agents were administered in three divided doses on days 1, 5 and 9. Tumor nodules were monitored two times per week by serial micrometer measurements by a single observer. Tumor size in treated animals was followed to day 21.
Results of studies with MCF-7 /HER-2 cells are shown in Figure 2 . The eect of various doses of rhuMAb HER-2 (Groups C ± F) on tumor volume was compared to that of control human IgG1 (Group A) and rhuMAb 4D5 (Group B). Marked inhibition of tumor growth relative to control was seen at all Figure 1 Growth of MCF-7 cells with or without HER-2 gene overexpression as xenografts in nude mice. MCF-7 parental cells (MCF ± PAR) were bioengineered with CON (normal-copy HER-2) or HER-2 (multi-copy HER-2) retroviral expression vectors as described in Materials and methods. Cells were inoculated subcutaneously in athymic mice which had been primed for 7 days with estradiol-17b. Tumor nodules were then monitored to day 28 Figure 2 Antitumor ecacy of various doses of rhuMAb HER-2 on human MCF-7 breast tumor xenografts in athymic mice. MCF-7 cells were engineered for overexpression of HER-2 receptor as described in Materials and methods. After 7 days, treatments were instituted with human IgG1 at 100 mg/kg (Group A); murine monoclonal antibody 4D5 at 25 mg/kg (Group B); or rhuMAb HER-2 at 3 mg/kg (Group C), 10 mg/kg (Group D), 30 mg/kg (Group E) or 100 mg/kg (Group F). Mean tumor size in each rhuMAb HER-2 group was compared to that in human IgG1-or murine 4D5-treated groups. Marked inhibition of mean day 21 tumor growth relative to control IgG1 was observed at all doses of rhuMAb HER-2 tested (P50.01). Animal weights on days 1 and 21 were not signi®cantly dierent (data not shown) doses of rhuMAb HER-2 tested (P50.01). Analyses of mean tumor volumes at day 21 indicate that the antitumor eect of rhuMAb HER-2 is dose-dependent (P50.01). The rhuMAb HER-2 at a dose of 100 mg/ kg had an eect comparable to murine 4D5 antibody at a dose of 25 mg/kg. It is notable that rhuMAb HER-2, even at the lowest dose tested (3 mg/kg), eectively suppressed tumor growth during the period of active treatment (i.e., day 1 through day 9). In independent control experiments, we also tested the eect of rhuMAb HER-2 at a dose of 30 mg/kg in estrogen-supplemented nude mice innoculated with MCF-7 / CON tumors at 50 ± 100 mm 3 in size. After 21 days of therapy as above, no signi®cant antitumor eect of the antibody was found in tumors induced by cells with a single-copy of the gene which express normal levels of the HER-2 receptor (data not shown).
A parallel study of rhuMAb HER-2 eects in CAOV3/HER-2 human ovarian cancer cells is shown in Figure 3 . As with the breast cancer cells, the antitumor eect of several doses of rhuMAb HER-2 (Groups C ± F) on human ovarian cancer cells was compared to that of control human IgG1 (Group A) and murine 4D5 (Group B) treatment over a 21 day period. Inhibition of tumor growth at day 21 relative to control IgG1 was observed at all doses of rhuMAb HER-2 tested. The degree of inhibition reached statistical signi®cance at the highest dose of rhuMAb HER-2 where a tenfold decrease in tumor size compared to control was found (P50.001). These data demonstrate that the tumor suppressive activity of the rhuMAb HER-2 monoclonal antibody is not restricted by cell or epithelial tissue type.
Eect of combined therapy with rhuMAb HER-2 and cisplatin in athymic mice with human breast tumor xenografts
In view of recent reports indicating that murine anti-HER-2 receptor antibodies have synergistic antitumor eects with cisplatin (Christen et al., 1991; Hancock et al., 1991; Shepard et al., 1991; Pietras et al., 1994) , experiments were conducted to evaluate potential enhanced eects of rhuMAb HER-2 when combined with the chemotherapeutic drug, cisplatin, on the growth of HER-2-overexpressing human breast cancer cells. The MCF-7 /HER-2 cells were cultivated in estrogen-primed female nude mice for 7 days and then randomized to seven treatment groups. The study design included mice treated with: human IgG1 control at 3 mg/kg (Group A); cisplatin at 0.25 mg/kg and IgG1 at 3 mg/kg (Group B); cisplatin at 0.75 mg/kg and IgG1 at 3 mg/kg (Group C); rhuMAb HER-2 at 1 mg/kg (Group D) and at 3 mg/kg (Group E); rhuMAb HER-2 at 1 mg/kg with cisplatin at 0.25 mg/kg (Group F); rhuMAb HER-2 at 1 mg/kg with cisplatin at 0.75 mg/kg (Group G); rhuMAb HER-2 at 3 mg/kg with cisplatin at 0.25 mg/kg (Group H); and rhuMAb HER-2 at 3 mg/kg with cisplatin at 0.75 mg/kg (Group I). The total doses of antibody indicated above were administered as three divided doses on days 1, 5 and 9. Those groups treated with cisplatin received a single injection of the drug 18 h after administration of the antibody. All agents were given as intraperitoneal injections. Tumor nodules were monitored up to day 21. Figure 4 shows the magnitude and time course of the eect of various doses of rhuMAb HER-2 with or Figure 3 Antitumor ecacy of various doses of rhuMAb HER-2 on human CAOV3 ovarian tumor xenografts in athymic mice. CAOV3 cells were engineered for overexpression of HER-2 receptor as described in Materials and methods. After 7 days, treatments were instituted with human IgG1 at 100 mg/kg (Group A); murine monoclonal antibody 4D5 at 25 mg/kg (Group B); or rhuMAb HER-2 at 3 mg/kg (Group C), 10 mg/kg (Group D), 30 mg/kg (Group E) or 100 mg/kg (Group F). The antitumor eect of the several doses of rhuMAb HER-2 was compared to that of control human IgG1 and 4D5 treatments over 21 days. Inhibition of tumor growth at day 21 relative to control IgG1 was observed at all doses of rhuMAb HER-2 tested, but only reached statistical signi®cance at the highest dose of rhuMAb HER-2 where a tenfold decrease in tumor size compared to control was found (P50.001). Animal weights on days 1 and 21 were not signi®cantly dierent (data not shown) Figure 4 Enhanced antitumor eects of the chemotherapeutic drug, cisplatin, when combined with rhuMAb HER-2. HER-2-overexpressing MCF-7 breast cancer cells were cultivated in estrogen-primed female nude mice for 7 days and then randomized to seven treatment groups. The study design included mice treated with: human IgG1 control at 3 mg/kg (Group A); cisplatin at 0.25 mg/kg and IgG1 at 3 mg/kg (Group B); cisplatin at 0.75 mg/kg and IgG1 at 3 mg/kg (Group C); rhuMAb HER-2 at 1 mg/kg (Group D) and at 3 mg/kg (Group E); rhuMAb HER2 at 1 mg/kg with cisplatin at 0.25 mg/kg (Group F); and rhuMAb HER-2 at 1 mg/kg with cisplatin at 0.75 mg/kg (Group G); rhuMAb HER-2 at 3 mg/kg with cisplatin at 0.25 mg/kg (Group H); and rhuMAb HER-2 at 3 mg/kg with cisplatin at 0.75 mg/kg (Group I). Total doses of antibody above were administered as three divided doses on days 1, 5 and 9. Groups treated with cisplatin received a single injection of the drug 18 h after antibody. All agents were given as rapid intraperitoneal injections. Tumor nodules were monitored until day 21 without cisplatin on tumor volume compared to control groups. Results at days 18 and 21 were comparable and are detailed here. Of mice receiving either rhuMAb HER-2 at low dose (Group D) or cisplatin with control IgG (Groups B,C), mean inhibition of tumor growth compared to control (Group A) was measurable but minimal (P40.05) and only attained statistical signi®cance in animals receiving 3 mg/kg of rhuMAb HER-2 (P50.01). In contrast, animals that received both rhuMAb HER-2 and a single injection of cisplatin displayed a marked reduction of 2 ± 16-fold in mean 21-day tumor volumes relative to control (P50.01). Moreover, average tumor sizes in animals injected with both rhuMAb HER-2 and cisplatin (i.e., Groups G ± I) were, with the exception of Group F, signi®cantly less than when comparable doses of either agent were given separately (P50.05). These data indicate an enhanced eect of cisplatin when administered with rhuMAb HER-2 and support the clinical application of these agents in combination.
Eect of order of administration of rhuMAb HER-2 and cisplatin on growth of human breast tumor xenografts in athymic mice
To evaluate the potential in¯uence of schedule of administration of rhuMAb HER-2 when combined with cisplatin on the growth of HER-2-overexpressing MCF-7 cells, the cells were cultivated in estrogenprimed female athymic mice for 14 days and then randomized to one of 18 treatment groups. The study design is outlined in Table 1 . Doses of antibody were administered as indicated in the Table at various times before or after cisplatin. All agents were given as intraperitoneal injections. Tumor nodules were monitored to day 21.
The eect of rhuMAb HER-2 given at various times before or after cisplatin on breast tumor volume compared to control groups is demonstrated in Figure  5 . In these experiments, rhuMAb HER-2 was given at 3 mg/kg, and cisplatin was used at a dose of 0.5 mg/kg. In Figure 5a , rhuMAb HER-2 is injected on days 1, 2, 3 or 5, with the antitumor eect compared to IgG control given at day 1. All treatments with antibody alone elicited a signi®cant growth suppression as compared to control (P50.05). In Figure 5b , cisplatin at 0.5 mg/kg is administered with IgG at days 1, 2, 3 or 5. Therapy with cisplatin on the several days tested also blocked tumor formation in athymic mice as compared to the IgG control group (P50.05).
Several dierent combination treatments with antibody and drug are presented in Figure 5c and d. As shown in Figure 5c , rhuMAb HER-2 is given on day 1, with cisplatin administration varying from day 1 through day 5. Each of these treatment protocols promoted signi®cant growth suppression as compared to the IgG control group (P50.01). With the exception of Groups 13 and 14 (c.f. Table 1) in which cisplatin followed antibody by 3 to 5 days, the groups exhibited signi®cantly more tumor growth inhibition than mice treated with cisplatin alone (P50.05). The ®nal set of treatment protocols is shown in Figure 5d which presents data from mice given cisplatin on day 1, with rhuMAb HER-2 administration varying from day 1 through day 5 (cf. Table 1 ). All treatments with cisplatin followed by antibody showed a signi®cant antitumor eect compared to IgG controls (P50.05); however, cisplatin followed by rhuMAb HER-2 at days 2 to 5 did not elicit greater tumor growth suppression than antibody given alone on corresponding days (P40.25). Moreover, administration of rhuMAb HER-2 at 1 ± 4 days after cisplatin (Groups 16 ± 18) showed less antitumor ecacy than those regimens in which antireceptor antibody preceded cisplatin (Groups 10 ± 12; P50.05). These data demonstrate that the order of antibody/cisplatin administration is critical and clearly aects the magnitude of observed antitumor responses in HER-2-overexpressing human breast cancer xenografts.
Eect of cyclic therapy with cisplatin and rhuMAb HER-2 on human breast tumor growth in nude mice
To evaluate the cytotoxic ecacy of repeated therapy with rhuMAb HER-2 in combination with cisplatin on the growth of HER-2-overexpressing MCF-7 cells, cells were cultivated in estrogen-primed female athymic mice for 14 days and then randomized to four groups for three cycles of therapy. Treatment groups included human IgG1 control at 30 mg/kg (CON), cisplatin at 5 mg/kg with human IgG1 (DDP), rhuMAb HER-2 at 30 mg/kg (rhuMAb) or combined cisplatin / rhuMAb (rhuMAb/ DDP) therapy. Doses of rhuMAb HER-2 antibody or IgG1 control were administered in divided doses on days 1, 5 and 9, repeated on days 21, 25 and 29 and once again on days 42, 46 and 50. The groups treated with cisplatin received a single injection of the drug immediately after administration of the antibody or IgG1. All agents were given as intraperitoneal injections, and tumor nodules were monitored until day 64. Figure 6 shows the eect of repeated doses of rhuMAb HER-2 with or without cisplatin on tumor volume compared to control groups. In mice receiving cisplatin with control IgG (DDP), mean tumor volumes compared to control (CON) were reduced over the 9-week treatment period (P50.001), but no complete tumor remissions were observed. Tumors exposed to rhuMAb HER-2 alone (rhuMAb) also showed reduced growth (P50.001) as compared to controls (CON), but, again, no complete tumor remissions were obtained. In contrast, combined drug/antibody therapy produced a marked reduction in tumor volumes compared to control values (P50.001), and ®ve of six animals receiving both rhuMAb HER-2 and cisplatin (rhuMAb/DDP) had complete tumor remissions after 2 ± 3 cycles of therapy, with a partial remission occurring in the remaining animal. Eects of combined drug-antibody therapy were signi®cantly dierent from those found with antibody or cisplatin treatment alone (P50.001). These data show markedly increased cytotoxicity of cisplatin when administered with rhuMAb HER-2 and support the potential clinical utility of these agents in combination.
Eect of cyclic therapy with doxorubicin and rhuMAb HER-2 on human breast tumor growth in nude mice
Prior work has shown some therapeutic advantage in the treatment of human tumors with anti-EGF receptor antibodies and doxorubicin (Aboud-Pirak et al., 1989) , a drug commonly used in the treatment of breast cancer. Although anthracyclines are not generally considered to be DNA-damaging agents, recent work suggests these agents may elicit some indirect covalent modi®cations of DNA in mammary tissue (Purewal and Liehr, 1993) . To evaluate the ecacy of therapy with rhuMAb HER-2 in combina- Table 1 .). (c) Mean tumor volumes of mice treated with human IgG1 on day 1 as compared to therapy with rhuMAb HER-2 on day 1 followed by cisplatin on days 1 ± 5 (c.f. Groups 1 and 10 ± 14 in Table 1 .). (d) Mean tumor volumes of mice treated with human IgG1 on day 1 as compared to therapy with cisplatin on day 1 followed by rhuMAb HER-2 on days 1 ± 5 (c.f. Groups 1 and 15 ± 18 in Table  1.) tion with doxorubicin on the growth of HER-2-overexpressing MCF-7 cells, cells were cultivated in estrogen-primed female athymic mice for 14 days and then randomized to four groups for three cycles of therapy as above. Treatment groups included human IgG1 control at 30 mg/kg (CON) doxorubicin at 5 mg/ kg with human IgG1 (DOXO), rhuMAb HER-2 at 30 mg/kg (rhuMAb) or combined doxorubicin/ rhuMAb (rhuMAb/DOXO) therapy. Doses of antibody or IgG1 indicated above were administered in divided doses on days 1, 5 and 9 and then repeated on days 21, 25 and 29 and ®nally on days 42, 46 and 50. Those groups treated with doxorubicin received a single injection of the drug immediately after administration of the rhuMAb HER-2 antibody or control IgG1. All agents were given as intraperitoneal injections. Tumor nodules were monitored to day 64. Figure 7 shows the eect of repeated doses of rhuMAb HER-2 with or without doxorubicin on tumor volume as compared to control groups. Mice receiving doxorubicin with control IgG (DOXO) had mean tumor volumes compared to control (CON) which were signi®cantly reduced over the 9-week treatment period (P50.01). Again, no complete tumor remissions were observed. Tumors exposed to rhuMAb HER-2 alone (rhuMAb) also showed reduced growth (P50.001) as compared to controls (CON), but, again none achieved complete tumor remissions. In contrast, over the 9-week treatment period, the combined drug/ antibody regimen produced a marked reduction in tumor volumes compared to control values (P50.001), with one of six animals receiving this combination (rhuMAb/DOXO) achieving a complete tumor remission after 2 ± 3 cycles of therapy, with partial remissions occurring in the remaining animals. Eects of combined drug-antibody therapy were signi®cantly dierent from those found with antibody treatment alone (P50.01). Although the magnitude of the combined doxorubicin-antibody eect is less than that found with cisplatin-antibody combinations (compare with Figure 6 ), this combination does provide a therapeutic advantage over treatment with either agent alone.
Eect of rhuMAb HER-2 in combination with chemotherapeutic drugs on unscheduled DNA synthesis After demonstrating a clear therapeutic advantage of the combination of rhuMAb HER-2 and DNA-reactive drugs in HER-2-overexpressing cells, experiments were designed to evaluate possible mechanisms for this phenomenon. Previous work has shown that the cellular accumulation of cisplatin within cells is not aected by HER-2 antireceptor antibody in breast cancer cells (32). In addition, using methods previously described (Andrews et al., 1988) , we ®nd no signi®cant eect of rhuMAb HER-2 at doses up to 100 mg/ml on Figure 6 Eect of cyclic therapy with cisplatin and rhuMAb HER-2 on growth of MCF-7/HER-2 breast tumor xenografts in nude mice over 64 days. Cells were cultivated in estrogen-primed female nude mice for 7 days and then randomized to four treatment groups. The study design included the following groups: human IgG1 control at 30 mg/kg given in divided doses at days 1, 4 and 9, and then repeated on days 21, 25 and 29 and ®nally on days 42, 46 and 50 (CON); IgG1 and cisplatin at 5 mg/kg given as a single dose on days 1, 21 and 42 (DDP); rhuMAb HER-2 at 30 mg/kg given in divided doses at days 1, 4 and 9, and then repeated on days 21, 25 and 29 and ®nally on days 42, 46 and 50 (rhuMAb); and cisplatin combined with rhuMAb HER-2 (rhuMAb/DDP). Those groups treated with cisplatin received a single injection of the drug immediately after administration of antibody or IgG1. All agents were given as rapid intraperitoneal injections. Tumor nodules were monitored until day 64 Figure 7 Eect of cyclic therapy with doxorubicin and rhuMAb HER-2 on growth of MCF-7/HER-2 breast tumor xenografts in nude mice over 64 days. Cells were cultivated in estrogen-primed female nude mice for 7 days and then randomized to four treatment groups. The study design included the following groups: human IgG1 control at 30 mg/ kg given in divided doses at days 1, 4 and 9 and then repeated on days 21, 25 and 29 and ®nally on days 42, 46 and 50 (CON); IgG1 and doxorubicin at 5 mg/kg given as a single dose on days 1, 21 and 42 (DOXO); rhuMAb HER-2 at 30 mg/kg given in divided doses at days 1, 4 and 9 and then repeated on days 21, 25 and 29 and ®nally on days 42, 46 and 50 (rhuMAb); and doxorubicin combined with rhuMAb HER-2 (rhuMAb/DOXO). Those groups treated with doxorubicin received a single injection of the drug immediately after administration of antibody or IgG1. All agents were given as rapid intraperitoneal injections. Tumor nodules were monitored until day 64 accumulation of [ 14 C]doxorubicin by MCF-7/HER-2 cells over 2 h (data not shown), indicating that the therapeutic advantage found with this combination also does not occur by altered cell accumulation of the anthracycline.
DNA repair is well known to play an important role in the recovery of cells from the toxicity of DNAreactive drugs (Zhen et al., 1992; Nielsen et al., 1996) , and changes in cisplatin-induced DNA repair have been reported to occur in HER-2-overexpressing cells after treatment with antibodies to HER-2 receptor (Pietras et al., 1994; Arteaga et al., 1994) . To further evaluate the role of DNA repair as an explanation for the therapeutic advantage of antireceptor antibody and DNA-reactive drugs, we measured unscheduled DNA synthesis induced by cisplatin and doxorubicin in MCF-7 cells (Figure 8 ). As previously reported, treatment of breast cells with cisplatin alone elicits signi®cant increases in unscheduled DNA synthesis as determined by thymidine incorporation into DNA (Pietras et al., 1994) . These data indicate an active DNA repair apparatus in MCF-7 parental, control and HER-2-overexpressing cells (P50.01; Figure 8 ). Treatment with rhuMAb HER-2, however, signi®cantly blocks this cisplatin-induced increase in DNA synthesis in MCF-7/HER-2 cells (P50.001), but does not aect DNA repair in MCF-7 parental or control cells (Figure 8) .
Although anthracyclines are not generally considered to be DNA-damaging agents, recent data suggests these agents may elicit indirect covalent modi®cations of DNA in mammary tissue (Purewal and Liehr, 1993; Nielsen et al., 1996) . To evaluate the potential eect of doxorubicin on DNA repair pathways, unscheduled DNA synthesis after doxorubicin in MCF-7 cells was also measured. Treatment of the breast cells with doxorubicin alone provoked a small, but measurable increase in unscheduled DNA synthesis (P50.01; Figure 8 ). Treatment with rhuMAb HER-2 again signi®cantly inhibits this doxorubicin-related increase in DNA repair in MCF/HER-2 cells. To con®rm that this phenomenon was speci®cally due to HER-2 overexpression, it was tested in non-HER-2-overexpressing cells, i.e. parental and control MCF-7 cells. The drug-related eect on unscheduled DNA synthesis was not aected by antireceptor antibody in these cells, con®rming the antibody speci®city, interfering with DNA repair only in those cells overexpressing the HER-2 receptor.
Eect of rhuMAb HER-2 in combination with cisplatin on formation and repair of cisplatin-induced DNA adducts in the DNA of MCF-7 cells with HER-2 overexpression Since measures of unscheduled DNA synthesis provide only an indirect assessment of actual DNA repair, we sought to obtain direct data on the formation and removal of cisplatin-induced lesions in total genomic DNA of human breast cancer cells (Table 2) . MCF-7/HER-2 cells were treated with 200 mM cisplatin for 1 h at 378C, washed and then harvested at 0 or 20 h after the initial cisplatin treatment. To test the eect of antireceptor antibody, cells were ®rst exposed to rhuMAb HER-2 (100 mg/ ml) or control solution for 4 h prior to cisplatin treatment. After cisplatin exposure and cell washing, rhuMAb HER-2 was maintained in the culture medium at 100 mg/ml for the repair times indicated in Table 2. Table 2 shows data for the formation and removal of cisplatin-DNA adducts from the genomic DNA of cells treated with or without antireceptor antibody in three separate experiments. Treatment of HER-2-overexpressing MCF-7 cells with rhuMAb HER-2 prior to cisplatin promoted a signi®cant reduction in the extent of DNA repair to 61% of that found in cells not treated with the antibody (P50.05). This result con®rms that rhuMAb HER-2 antibody is eective in blocking DNA repair of cisplatin-induced DNA adducts in human breast cancer cells with HER-2 overexpression.
Eect of time of administration of HER-2 antireceptor antibody on repair of cisplatin-damaged reporter DNA in human breast tumor cells
To test the hypothesis that the time of administration of HER-2 antireceptor antibody may be critical for Figure 8 DNA repair (unscheduled DNA synthesis) in human MCF-7 breast carcinoma cells. Unscheduled DNA synthesis (UDS) was determined as described in Materials and methods. UDS was measured in MCF-7 parental (PAR), control (CON) and HER-2-overexpressing (HER-2) cells after treatment with control, rhuMAb HER-2 (200 mg/ml), cisplatin (DDP; 5 mM), doxorubicin (DOXO; 1 mM), 5 mM cisplatin in combination with 200 mg/ml rhuMAb HER-2 (DDP/rhuMAb), or 1 mM doxorubicin in combination with 200 mg/ml rhuMAb HER-2 (DOXO/ rhuMAb). Doses selected for chemotherapeutic drugs were based on biologic dose-response data from preliminary experiments and from prior reports (Sawyer et al., 1988; Pietras et al., 1994; Boven et al., 1996; Kurbacher et al., 1996) Per cent repair was estimated in three independent experiments as described elsewhere (Pietras et al., 1994) using cisplatin adduct counts at 0 and 20 h as shown here. The latter counts were corrected for DNA replication using established methods (Jones et al., 1991; Pietras et al., 1994) . Signi®cantly dierent from control at P50.05 in three independent experiments blockade of DNA repair, a CMV-driven b-galactosidase reporter plasmid was exposed to cisplatin in vitro and then transfected into MCF-7/HER-2 cells. At 24 h after transfection, the extent of repair was assayed by measuring reporter DNA expression in MCF-7/HER-2 cells that were incubated with rhuMAb HER-2 at 72 or 24 h prior to or at the end of the transfection (0 h). The transfected cells were stained with 5-bromo-4-chloro-3-indolyl-b-Dgalactopyranoside, a substrate for b-galactosidase, to distinguish b-galactosidase-positive and -negative cells. In the presence of substrate, cells expressing bacterial b-galactosidase appeared blue and the percentage of stained cells was quantitated (see Figure 9 ). These data demonstrate that, as in the in vivo experiments above, antibody-modulated repair of cisplatin-damaged DNA is optimal when drug and antibody are administered in close temporal proximity. The timing of antibody/cisplatin administration is critical and clearly aects the magnitude of observed responses in HER-2-overexpressing human breast cancer cells.
Antireceptor antibodies disrupt regulation of p21/WAF1 expression in breast cancer cells with HER-2 overexpression.
The CDK inhibitor, p21/WAF1, is a critical mediator of the cellular response to DNA damage. We have assessed the activity of p21/WAF1 in response to cisplatin-induced DNA damage in MCF-7/HER-2 cells in the presence and in the absence of rhuMAb HER-2. Transcripts of p21/WAF1 were assessed by Northern blot analysis. MCF-7/HER-2 cells were treated with 100 mg/ml rhuMAb HER-2 alone or in combination with cisplatin treatment. Paired cells were treated with control solution or cisplatin alone. After 2 h or 24 h, Figure 9 Time of administration of HER-2 antireceptor antibody aects repair of cisplatin-damaged reporter DNA in human breast cancer cells. CMV-driven b-galactosidase reporter plasmid was exposed to cisplatin in vitro and then transfected into MCF-7/ HER-2 cells. At 24 h after transfection was completed, the extent of repair was assayed by measuring reporter DNA expression in MCF-7/HER-2 cells that were incubated without antibody (CON) or with rhuMAb HER-2 at 72 h or 24 h prior to transfection or at the end of the transfection (0 h). In each rhuMAb HER-2 group, cells were incubated with antibody for 2-h periods and were then washed and incubated further in the absence of antibody. Reporter activity is presented as the percentage of blue-stained cells in the presence of 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside, a substrate for b-galactosidase Figure 10 Monoclonal antibody to HER-2 growth factor receptor alters p21/WAF1 transcript and protein levels after cisplatin treatment of human breast cancer cells with HER-2 overexpression. After 2 h or 24 h, cells were processed for preparation of RNA or protein and determination of p21/ WAF1 levels by established methods. (a) MCF-7/CON cells were treated with control solution (Cn), cisplatin (DDP, 5 mM), 100 mg/ml rhuMAb HER-2 (Ab) or rhuMAb HER-2 in combination with cisplatin (Ab/DDP) for 2 h or 24 h as indicated. Cell RNA was subjected to Northern blot analysis, with hybridization of the resulting blot with p21/WAF1 cDNA. The transcripts are predicted to be 2.1 kb, a size corresponding to that of human p21/WAF1 mRNA (El-Deiry et al., 1993) . (b) MCF-7/HER-2 cells were treated with control solution (Cn), 100 mg/ml rhuMAb HER-2 alone (Ab), cisplatin (DDP, 5 mM), or 100 mg/ml rhuMAb HER-2 in combination with cisplatin (Ab/ DDP). Cell RNA was subjected to Northern blot analysis, with hybridization of the resulting blot with p21/WAF1 cDNA. (c) MCF-7/HER-2 cells were treated with control solution (Cn), 100 mg/ml rhuMAb HER-2 (Ab), cisplatin (DDP, 5 mM) or rhuMAb HER-2 in combination with cisplatin (Ab/DDP) for 2 h or 24 h as indicated. On Western blotting with anti-p21/ WAF1 antibody, p21/WAF1 was found to occur as a 21-kd protein. (d) MCF-7/HER-2 cells were treated with control solution (Cn), 100 mg/ml rhuMAb HER-2 (Ab), cisplatin (DDP, 5 mM) or rhuMAb HER-2 in combination with cisplatin (Ab/ DDP) for 2 h or 24 h as indicated. On Western blotting with anti-PCNA antibody, proliferating cell nuclear antigen was found to occur as a 36 kd protein. See text for additional details cells were processed for preparation of RNA and determination of p21/WAF1 transcripts. The results show induction of p21/WAF1 transcripts at 2 h and 24 h after cisplatin treatment (Figure 10 ). However, increased levels of p21/WAF1 transcript are not sustained in MCF-7/HER-2 cells exposed to cisplatin in the presence of rhuMAb HER-2. Although the transcript level increases at 2 h, it is comparable to control levels of transcript by 24 h (Figure 10 ). The level of p21/WAF1 at 24 h is markedly less than the eect of cisplatin given without antibody. A reduction in the basal level of p21/WAF1 also occurred after 24 h exposure to antibody alone as compared with controls.
Western analyses of the level of p21/WAF1 protein in MCF-7/HER-2 cells likewise show enhanced amounts of the protein at 2 h and 24 h after cisplatin (Figure 10) . However, as found in Northern studies, treatment of cells with antireceptor antibody elicits a reduced level of p21/WAF1 protein under basal conditions and blunts the anticipated response to chemotherapy at 24 h, as compared to controls. In contrast, the level of proliferating cell nuclear antigen (PCNA) is unchanged at 2 h and 24 h after cisplatin with or without rhuMAb HER-2 treatment ( Figure  10 ). These results are consistent with independent reports on depletion of p21/WAF1 after withdrawal of growth factors (Canman et al., 1995) and suggest an important role for growth factor pathways in modulating the activity of proteins which regulate DNA repair.
Discussion
HER-2 growth factor receptors which are overexpressed in approximately one-third of human breast and ovarian cancers are a logical target for the development of new therapeutic approaches which exploit the alteration. The current data demonstrate that a recombinant humanized anti-HER-2 receptor monoclonal antibody, similar to the murine antibody 4D5 from which it was derived (Hudziak et al., 1989; Fendly et al., 1990) , inhibits growth of HER-2-overexpressing human breast and ovarian tumor xenografts in athymic mice. In addition, the magnitude of growth inhibition is directly related to dose of rhuMAb HER-2, with the highest dose tested showing a 10 ± 14-fold decrease in tumor size compared to control. These data provide strong evidence for an in vivo antiproliferative eect of rhuMAb HER-2 in tumors derived from cells which overexpress HER-2 protein. In addition, they are consistent with the initial observations which demonstrated that monoclonal antibodies against the extracellular domain of the HER-2 receptor can suppress tumorigenesis of HER-2-transformed NIH3T3 and NR6 cells (Drebin et al., 1988; Chazin et al., 1992) as well as inhibit the growth of human breast carcinoma cells overexpressing the HER-2 gene product in vitro (Hudziak et al., 1989) . The growth inhibitory eects of antibody alone, however, are cytostatic, with tumor growth recurring after discontinuation of antibody administration.
In view of earlier reports by Aboud-Pirak et al. (1988) and the subsequent studies of our and other laboratories (Christen et al., 1991; Hancock et al., 1991; Shepard et al., 1991; Pietras et al., 1994; Arteaga et al., 1994; Dixit et al., 1997) indicating potentiation of tumor cell cytotoxic eects using antireceptor antibody and chemotherapeutic agents, therapy with antibody in combination with cisplatin or doxorubicin was tested in the current study. The present in vivo data con®rm the considerable potentiation of cisplatin cytotoxicity and some potentiation of anthracycline cytotoxicity by combined treatment with rhuMAb HER-2 in human breast cancer cells which overexpress the HER-2 receptor. The eect is especially pronounced when multiple cycles of combined treatment are administered, with up to a 1000-fold therapeutic dierence in cisplatin/antibody therapy and a 200-fold dierence in doxorubicin/antibody therapy. The therapeutic advantage of combined treatment with antibody and cisplatin is clearly evident since tumor remissions were found which could not be achieved when either agent was administered alone at sublethal doses (Berenbaum, 1989; Wampler et al., 1992) . Using a formal medianeects approach (Chou and Talalay, 1984) , a true synergistic decrease in human cancer cell growth in vitro and in vivo by combination therapy with cisplatin and the anti-HER-2 antibody has been shown (Pietras et al., 1994) . The current study also demonstrates that timing of antireceptor antibody and cisplatin administration is critical in promoting an optimal in vivo antitumor eect. Treatment with cisplatin and rhuMAb HER-2 in relatively close temporal proximity appears necessary for greatest suppression of human breast tumor growth, with optimum inhibition occurring when the antibody is given shortly before or simultaneously with cisplatin. The profound antitumor toxicity of cisplatin together with rhuMAb HER-2 administered in repeated therapy as detailed here supports the use of these agents in combination over multiple courses.
Although the molecular consequences of cisplatin (Chu, 1994) and doxorubicin (Sawyer et al., 1988; Purewal and Liehr, 1993; Cutts et al., 1994; Nielsen et al., 1996) therapy and antireceptor antibody-receptor interactions (Drebin et al., 1988; Sarup et al., 1991; Scott et al., 1991) are incompletely understood, the present evidence is consistent with independent reports which show that antibodies to the HER-2 receptor not only elicit growth inhibition on their own (Drebin et al., 1988; Hudziak et al., 1989; Chazin et al., 1992) but can modulate the sensitivity to DNA-reactive drugs (Hancock et al., 1991; Shepard et al., 1991; Pietras et al., 1994) . Doxorubicin is generally considered to act as a DNA-intercalating agent, but recent reports suggest that anthracyclines might also indirectly promote covalent modi®cation of DNA and possibly induce adduct formation (Sawyer et al., 1988; Purewal and Liehr, 1993; Cutts et al., 1994) . Cisplatin tends to produce intrastrand adducts and interstrand crosslinks in DNA and also evokes changes in the expression and association of certain sequence-speci®c binding proteins with damaged DNA (Chu, 1994) . Unlike doxorubicin, however, a signi®cant role of DNA repair has been well-established in the recovery of cells from the toxicity of cisplatin (Chu, 1994) . Cells which incur DNA damage exhibit cell cycle delays, and these delays are considered to be critical to allow repair of DNA before continuing through the cell cycle to mitosis (Sorenson et al., 1990) . Miscommunication in these complex signal pathways, perhaps due to antireceptor antibody or to inappropriate ligand stimulation (Kinzel et al., 1990) , could lead to lethal consequences for the cell. Similarly, tyrosine kinase inhibitors which preferentially suppress HER-2 kinase have been found to sensitize HER-2-overexpressing lung cancer cells to anticancer drugs that damage DNA (Zhang and Hung, 1996; Tsai et al., 1996) . Another link between receptor signal transduction pathways and cisplatin sensitivity has been found to occur on modulation of protein kinase C activity (Hofman et al., 1988; Isonishi et al., 1990) , an enzyme involved in signal transduction to the nucleus (Olson et al., 1993) . This signal pathway is known to be down-regulated by long exposure of breast cancer cells to the 4D5 anti-HER-2 antibody (Hancock et al., 1991; Sarup et al., 1991) . It is clear that further mechanistic study of this phenomenon is required to render a full biologic explanation for growth factor receptor-chemotherapeutic drug interactions and the in vivo scheduledependency of this eect.
In p21/WAF17/7 cancer cells, p21/WAF1 deficiency is associated with a prominent defect in DNA repair (McDonald et al., 1996) . Although induction of the cyclin-dependent kinase inhibitor, p21/WAF1, in response to DNA damage occurs primarily through a transcriptional mechanism involving the tumor suppressor protein p53 (El-Diery et al., 1993) , recent work suggests that growth factors may provide an alternative pathway for regulation of p21/WAF1 expression. In the case of growth factor stimulatory pathways, induction of p21/WAF1 appears not to require p53 and may be activated instead by mitogen-activated protein kinase (Liu et al., 1996) . Withdrawal of growth factors in vitro has also been associated with downregulation of p21/WAF1 expression and with enhanced cell killing in response to DNA damage. The present work provides further evidence that the growth factor receptor, HER-2, can modulate DNA damage response pathways in breast cancer cells (Pietras et al., 1994; Arteaga et al., 1994) and suggests that this crosscommunication may involve modulation of p21/ WAF1. Others have reported recently that heregulin, a natural ligand to HER-2/HER-3 heterodimers, promotes the tyrosine phosphorylation of HER-2 receptor and the increased expression of p21/WAF1 in MCF-7 cells with HER-2 overexpression (Bacus et al., 1996) . We have assessed the activity of p21/WAF1 in response to DNA damage in MCF-7/HER-2 cells in the presence and in the absence of rhuMAb HER-2 antibody. Transcripts of p21/WAF1 showed signi®cant induction at 2 h and 24 h after cisplatin treatment. However, increased levels of p21/WAF1 transcript were not sustained in MCF-7/HER-2 cells exposed to chemotherapy in the presence of rhuMAb HER-2. The level of p21/WAF1 at 24 h is less than the eect of cisplatin given without antibody. A notable reduction in the basal level of p21/WAF1 also occurred after 24 h exposure to antibody alone as compared with controls. These results and independent reports on depletion of p21/WAF1 after withdrawal of growth factors (Canman et al., 1995) suggest an important role for growth factor pathways in modulating the activity of proteins which regulate DNA repair (Tsai et al., 1996) . Dysregulation of p21/WAF1 occurs after treatment with antireceptor antibody, and this event appears to adversely in¯uence the cell response to DNA damage.
Future work will be required to test the hypothesis that mitogen-activated protein kinase or other components of the HER-2 signaling pathway (Tsai et al., 1996; Lewis et al., 1996; Yen et al., 1997) play a role in the regulation of p21/WAF1. On binding of heregulin ligand, transient phosphorylation of HER-2 protein occurs, and this promotes downstream activation of MAP kinase (Marte et al., 1995; Reese and Slamon, 1997) . In contrast, antibodies to HER-2 receptor generally induce prolonged phosphorylation and down-regulation of HER-2 protein and disrupt the association of HER-2 with HER-3 Graus-Porta et al., 1995; Marte et al., 1995; Reese and Slamon, 1997) . Some anti-HER-2 receptor antibodies act as partial agonists and promote weak or no activation of MAP kinase. As anti-HER-2 antibodies, tyrosine kinase inhibitors with speci®city for HER-2 kinase are also known to enhance the sensitivity of HER-2-overexpressing cancer cells to DNA-damaging agents (Aboud-Pirak et al., 1989; Tsai et al., 1996) . Although the activity of rhuMAb HER-2 remains to be fully characterized, downstream eects of HER-2 stimulation, such as activation of MAP kinase, are likely to be aected by rhuMAb HER-2.
Signi®cant data support our hypothesis that p21/ WAF1 may play a vital role in mediating rhuMAb HER-2 eects on DNA damage pathways in the breast cancer cell. However, alterations in other regulatory proteins, including p53, MDM2 and GADD45, may also contribute to the process observed in the present work (Kastan et al., 1991; Chen et al., 1994; Canman et al., 1995) . Nevertheless, the available evidence suggests that pathways of DNA replication, DNA repair and DNA degradation may have common regulatory elements, with the ®nal outcome at a cellular level dependent on the extent of DNA damage . Growth factor receptors are likely to play a signi®cant regulatory role in this process, and manipulation of this pathway in the clinic with rhuMAb HER-2 may provide therapeutic bene®t to patients with HER-2-overexpressing breast cancer.
A further aspect of the present ®ndings is the possibility that HER-2 overexpression is linked to genesis of resistance to chemotherapeutic agents. Development of the drug-resistant, metastatic phenotype is responsible for the bulk of treatment failures in breast cancer (Harris et al., 1992) , and involvement of oncogenes in drug resistance was proposed by Scanlon et al. (1989) . Further evidence in support of this hypothesis has been published (Isonishi et al., 1991; Benz et al., 1993) . The potential role of HER-2 protooncogenes in modulation of chemotherapeutic drug sensitivity has been suggested from retrospective analysis of results of several therapeutic clinical studies (Allred et al., 1992; Gusterson et al., 1992; Muss et al., 1994) and from limited laboratory studies (Benz et al., 1993; Tsai et al., 1993) . If correct, these ®ndings could have important implications in patient management and treatment decisions. Assessment of HER-2 receptor overexpression already provides additional prognostic information in patients with both nodepositive (Slamon et al., 1987; 1989a; Van Diest et al., 1992) and node-negative (Ro et al., 1989; Press et al., 1993; Seshadri et al., 1993) breast cancer. Clues for the in¯uence of HER-2 signaling pathways on chemotherapeutic drug resistance require extension of clinical and laboratory investigations similar to those already reported (Benz et al., 1993; Tsai et al., 1993; Pegram et al., 1997) .
Treatment of human cancers requires new approaches designed to minimize toxicity to normal cells and maximize damage to tumor targets. Therapy directed at speci®c alterations unique to the tumor cell should prove more rational, less toxic and potentially more therapeutic. Remission of human HER-2-overexpressing breast tumors in nude mice after combined therapy with cisplatin and rhuMAb HER-2 oers the potential to achieve such a goal. This phenomenon, which we have termed receptor-enhanced chemosensitivity (REC; Pietras et al., 1994) has already been implemented in ongoing phase II ± III clinical combination chemotherapy trials in human subjects (Pegram et al., 1995) . The potential speci®city of the therapeutic use of anti-HER-2 antibodies to alter DNA repair in such a way as to speci®cally render HER-2 overexpressing cells more sensitive to certain drugs is bolstered by the present ®ndings and by independent reports showing little to no reactivity of such antibodies with most normal or non-overexpressing cells (Press et al., 1990; Pietras et al., 1994) . This should allow us to exploit the overexpression of the HER-2 gene in many breast and ovarian cancers to develop new and more rational approaches to the therapy of these diseases. In view of some of the potential obstacles and costs to long-term monoclonal antibody therapies in human cancer, an alternative therapeutic use of antireceptor antibodies may be in combination with cytotoxic agents to achieve optimal cytocidal eects rather than cytostasis.
Materials and methods

Cell lines and cell culture
The well-characterized human breast carcinoma cell line, MCF-7, and the human ovarian carcinoma cell line designated CAOV3 were obtained from American Type Culture Collection (Rockville, MD). All cells were cultured in RPMI 1640 medium supplemented with 10% heatinactivated fetal bovine serum, 2 mM freshly added glutamine and 1% penicillin G-streptomycin-fungizone solution (Irvine Scienti®c, Santa Ana, CA).
Transfections and ampli®cation/overexpression of human HER-2 gene in human cells
Human ovarian CAOV3 and breast MCF-7 carcinoma cells with normal levels of HER-2 gene expression were transfected with full-length cDNA of the human HER-2 gene. The latter was cloned from a primary human breast cancer specimen and characterized previously in our laboratory (Slamon et al., 1987 (Slamon et al., , 1989b Chazin et al., 1992) . The vector for introduction of HER-2 gene into human cells contained the full-length human HER-2 gene coding sequence ligated into the replication-defective retroviral expression vector, pLXSN (Miller and Rosman, 1989; Chazin et al., 1992) . This was achieved by ligating a 3.8 kb NcoI to MstII fragment containing the full HER-2 coding sequence, without the polyadenylation signal, into an amphotrophic retroviral expression vector with a Moloney murine leukemia virus (MMLV) promoter, a neomycin phosphotransferase gene and a packaging signal, but devoid of viral protein coding sequences; thus rendering the virus replication-defective. The pLXSN construct has an extended packaging signal for high virus titre as well as a mutated gag start codon and a shortened envelope region to decrease the risk of helper virus generation (Miller and Rosman, 1989; Chazin et al., 1992) . Virus-producing cells were prepared by a transient rescue procedure as described before (Miller and Rosman, 1989; Chazin et al., 1992) . As noted above, this vector also contains a neomycin resistance gene (neomycin phosphotransferase) which confers cellular resistance to the aminoglycoside antibiotic G418, thus allowing selection of primary infectants. The pLXSN vector devoid of HER-2 sequences (designated CON) but containing the neomycin phosphotransferase gene was packaged in an identical fashion and served as a retroviral control in appropriate experiments. Ovarian and breast carcinoma cells were infected as previously described (Chazin et al., 1992) . Cell lines established by this method of gene transfer were characterized at the DNA, RNA, protein and immunohistochemical level for copy number and expression level of HER-2 gene as reported elsewhere (Slamon et al., 1987; Chazin et al., 1992) .
Tumor formation in nude mice
Breast and ovarian cells were injected subcutaneously at 4 ± 5610 7 cells/animal in the mid-back region of female athymic mice (20 ± 25 gm). Mice from an inbred Swiss nude strain and from an outbred CD1 nu/nu strain (Charles River, Cambridge, MA) were used. Mice were maintained and handled under aseptic conditions. Animals were allowed free access to food and water throughout the study. Prior to tumor cell innoculation, all mice were primed for 7 days with 17b-estradiol introduced subcutaneously in a biodegradable carrier-binder (1.7 mg estradiol/ pellet; Innovative Research of America, Inc.). A period of 7 to 14 days elapsed to allow formation of tumor nodules. Animals were then randomized into uniform groups based on animal weight and tumor volume at the start of the experiment. Animals (5 ± 7 mice/group) were treated via i.p. injection. Animals received either an isotype-matched IgG1 control antibody, the murine 4D5 antibody, the rhuMAb 4D5 HER-2 antibody, cisplatin (DDP, cis-diamminedichloroplatinum(II); Bristol-Meyers, Squibb), doxorubicin or a combination treatment of the above as designated in the results section. Tumor nodules were monitored by micrometer measurements, with tumor volume calculated as the product of length6width6height. Tumor tissue was analysed for HER-2 receptor expression by established immunohistochemical methods (Slamon et al., 1987; Chazin et al., 1992) .
Monoclonal antibodies
Anti-HER-2 receptor monoclonal antibody 4D5 (2.5 mg/ ml; Lot No.G088AL/S9839AX) was prepared as previously described . Methods for construction of a humanized form of 4D5 containing only the antigenbinding loops from murine 4D5 and human variable region framework residues plus IgG1 constant domains (rhuMAb HER2 at 5.15 mg/ml; Lot No.GN1450/M3-RD168) were reported elsewhere . Human IgG1 (5.3 mg/ml) was used as control solution in appropriate experiments. Our choices for dose and schedule of therapy were based on results of prior pharmacokinetic studies using murine monoclonal antibody 4D5 and rhuMAb HER-2 DeSantes et al., 1992; Pietras et al., 1994) . These data showed that measures of serum clearance and permanence times in serum are similar for the humanized and native murine monoclonal antibodies. Maintenance of a serum antibody concentration in the range of 10 mg/ml required a dose of 42 mg/kg mouse body weight given every 4 days. Although time variant processes such as production of an antiglobulin response (mouse anti-human antibody) can occur in these systems, this eect has not been observed in studies with the rhuMAb HER-2 antibody. In athymic mice receiving twice-weekly i.p. doses of humanized antibody for 7 weeks, no enhanced immune clearance of humanized HER-2 antibody and no anti-humanized MAb antibodies have been measured in athymic mouse serum samples. Athymic mice were randomized to receive low (1 ± 3 mg/kg/dose) or high (10 ± 100 mg/kg/dose) doses of rhuMAb HER-2. Equal volumes of the agents were given.
Unscheduled DNA synthesis
Unscheduled DNA synthesis, DNA repair which is nonsemiconservative in nature, was determined by established methods (Pietras et al., 1994) . Cell monolayers were preincubated with or without antibody in argininede®cient, reduced serum (0.5%) media for 5 h, followed by exposure to hyroxyurea for 1 h. Cells were then treated with cisplatin or doxorubicin (in the presence of hydroxyurea) for 1 h and ®nally incubated with [ 3 H]thymidine and hydroxyurea for 3 h. Cell groups were harvested, and cellular DNA was bound to glass ®ber ®lters and collected for liquid scintillation counting of [ 3 H]thymidine incorporation/group.
Detection of genomic cisplatin adducts
Cells were cultivated in vitro to 60 ± 70% con¯uence. For 12 h prior to the start of the experiment, cells were labeled with 3 H-thymidine at 0.1 mCi/ml in order to provide a correction factor for any cellular replication during the course of the experiment (Jones et al., 1991; Pietras et al., 1994) . Thereafter, cells were incubated in fresh medium with rhuMAb HER-2 at 200 mg/ml or control solution for 4 h. The cells were then exposed to 200 mM cisplatin (freshly made) for 1 h, washed in cisplatin-free media and harvested at 0 and 20 h after the cisplatin treatment. Cells treated with or without rhuMAb HER-2 were maintained in the same media after removal of the drug. Harvested cells were pelleted and stored at 7208C until DNA isolation. DNA was isolated and prepared as described before (Pietras et al., 1994) . Total platinum content was assessed by atomic absorption spectrometry using a PerkinElmer Zeeman spectrometer (Zhen et al., 1992) .
In vivo repair of reporter DNA damaged by cisplatin Introduction of cisplatin-damaged reporter DNA into breast tumor cells was carried out by established methods. Prior to transfection, CMV-driven b-galactosidase (pCMVb; Clontech), a reporter DNA, was prepared without or with exposure to cisplatin in vitro as before (McDonald et al., 1996) . For transfection experiments, cells were plated 72 h prior to transfection, and transfections with internal controls for transfection eciency were carried out as described previously (McDonald et al., 1996) . In these transfection experiments, 1.5 mg undamaged or cisplatindamaged DNA was used. At 24 h after transfection, the extent of repair was assayed by measuring reporter DNA expression. The transfected cells were stained with 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside, a substrate for b-galactosidase, to distinguish b-galactosidase-positive and -negative cells. In the presence of substrate, cells expressing bacterial b-galactosidase appeared blue and the percentage of stained cells was quantitated.
Measurement of p21/WAF1 transcript and protein levels
Transcripts of p21/WAF1 were determined by Northern blot analysis, using a protocol as before (Slamon et al., 1987; 1989a; El-Diery et al., 1993; Pietras et al., 1995) . In brief, breast cancer cells with and without HER-2 overexpression were treated with or without rhuMAb HER-2 for 4 h before exposure to chemotherapy. Cells were then maintained for 2 h and 24 h prior to harvesting and processing for collection of RNA. After Northern blot analysis, the resulting blots were hybridized with p21/ WAF1 cDNA (generously provided by Dr Bert Vogelstein).
Western analyses of the level of p21/WAF1 protein in breast cancer cells were conducted with methods as before (Pietras et al., 1995) . We assessed p21/WAF1 protein in response to DNA damage in breast cancer cells in the presence and in the absence of growth factor receptor antibody. Breast cancer cells with and without HER-2 overexpression were treated with 100 mg/ml rhuMAb HER-2 for 4 h before exposure to cisplatin. Cells were then maintained for 2 h and 24 h prior to harvesting and processing of cell lysates for electrophoresis (Pietras et al., 1995) . Immunoblotting was done with monoclonal antibody 6B6 with speci®city for human p21/WAF1 (Pharmingen). In other studies, immunoblotting was also done with monoclonal antibody to proliferating cell nuclear antigen (PCNA; Santa Cruz Biotechnology).
Statistical analyses
Analysis of variance (ANOVA) was conducted on tumor size data at each time point. In each group, only data from animals surviving through day 21 were included in statistical assessments. Average tumor size in each treated group was compared to that in the appropriate control group via a two-tailed t-test using the pooled error variance from the ANOVA (Campbell, 1976) .
